Melphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexamethasone (VBAM Dex) Induction Chemotherapy and Interferon Maintenance Treatment in Multiple Myeloma
- 1 January 1990
- journal article
- clinical trial
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 13 (6) , 458-460
- https://doi.org/10.1159/000216820
Abstract
277 untreated multiple myeloma patients of stage I (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n = 14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-Α maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was > 36 months in stage II and 11 months in stage III patients.Keywords
This publication has 0 references indexed in Scilit: